18983288589(微信同号)
18983288589(微信同号)
18908392210(微信同号)
18980413049
2017-10-20
FDA-2017-D-6133
指导原则
美国
现行有效
/
美国食品药品监督管理局(FDA)
GUIDANCE DOCUMENT
Not for implementation. Contains non-binding recommendations.
The purpose of this guidance is to help establishments and facilities subject to Title 21 of the Code of Federal Regulations (21 CFR) part 117 (part 117) or 21 CFR part 507 (part 507) determine whether they are “solely engaged” in certain activities. Establishments and facilities “solely engaged” in certain activities are exempt from some or all requirements in parts 117 or 507.
FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe our current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in FDA guidances means that something is suggested or recommended, but not required.
For questions regarding this draft document as it relates to our regulation entitled “Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food,” contact the Center for Food Safety and Applied Nutrition (CFSAN) at 240-402-2166.
For questions regarding this draft document as it relates to our regulation entitled “Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Food for Animals,” contact the Center for Veterinary Medicine (CVM) at 240-402-6246.
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2017-D-6133.
Pharma CMC2024-10-15
摩熵医药(原药融云)2024-08-21
数屿医械2024-06-24
数屿医械2024-06-13
数屿医械2024-05-30
摩熵医药(原药融云)2024-05-27
药事纵横2024-02-28
药通社2023-12-26
摩熵医药(原药融云)2023-12-13
药通社2023-06-25
2024-11-15
2024-11-14
2024-11-01
2024-10-31
2024-10-30
2024-10-30
2024-10-30
2024-10-29
2024-10-28
2024-10-24
2024-10-24
2024-10-23
2024-10-23
2024-10-22
2024-10-21
2024-11-15
2024-11-14
2024-11-01
2024-10-31
2024-10-30
2024-10-24
2024-10-22
2024-10-21
2024-10-17
2024-10-17
2024-10-17
2024-10-17
2024-10-17
2024-10-16
2024-10-15
2024-11-14
2024-11-01
2024-10-31
2024-10-30
2024-10-30
2024-10-24
2024-10-22
2024-10-21
2024-10-17
2024-10-17
2024-10-17
2024-10-17
2024-10-17
2024-10-16
2024-10-15